Astellas Gene Therapies remains intent on treating X-linked Myotubular Myopathy (XLMTM) through a gene therapy—but instead of AAV-based resamirigene bilparvovec (AT132), Astellas is now partnering ...

University of California San Diego-led team has discovered that restoring a key cardiac protein called connexin‑43 in a mouse ...

The global cell and gene therapy market is experiencing explosive growth. Key growth factors include rising chronic/genetic disease prevalence, advancements in gene editing (CRISPR) and viral vectors, ...

Explore the role of the cPLA2 enzyme in brain inflammation related to Alzheimer’s disease and its potential as a therapeutic target.

On behalf of Lilly, Seamless will design and programme recombinases that can correct alterations in multiple genes involved ...

The global gene therapy market is experiencing rapid expansion, driven by advancements in CRISPR and viral vectors. The ...

A research team at the University of California San Diego has discovered a novel and promising method of treating arrhythmogenic cardiomyopathy (ACM), a rare inherited heart disease that can strike ...

Opus Genetics is conducting a trial for OPGx-MERTK gene therapy in Abu Dhabi, targeting MERTK-related retinitis pigmentosa using AAV-based delivery. The trial is a collaboration with Cleveland Clinic ...

Alzheimer’s may be driven far more by genetics than previously thought, with one gene playing an outsized role. Researchers ...

New one-dose treatment edits a gene in the liver, disabling the ANGPTL3 protein and significantly lowers cholesterol.

Lilly and German biotech Seamless Therapeutics will develop recombinase-based treatments for hearing loss.